Phase II Trial of Induction Chemotherapy for Advanced Sinonasal Squamous Cell Carcinoma [0.03%]
晚期鼻腔鼻窦癌术前化疗二期临床试验
Kevin J Contrera,Renata Ferrarotto,Brandon Gunn et al.
Kevin J Contrera et al.
Purpose: Outcomes after primary surgery for advanced sinonasal squamous cell carcinoma (SCC) are poor. We tested whether induction chemotherapy (IC) can improve disease control or organ preservation. ...
Personalized MRD Assessment in Peri-surgical ctDNA for Prognostic Prediction in Hepatocellular Carcinoma [0.03%]
术前和术后个性化ctDNA-MRD检测用于肝细胞癌患者的预后评估
Jie Hu,Haoran Tang,Can-Can Jia et al.
Jie Hu et al.
Objective: Detecting residual disease is a critical clinical requirement in the peri-surgical management of patients with resectable hepatocellular carcinoma (HCC). Previous studies focused on specific genomic regions exh...
A tumor-naive ctDNA assay detects minimal residual disease in resected stage II or III colorectal cancer and predicts recurrence: subset analysis from the GALAXY study in CIRCULATE-Japan [0.03%]
无肿瘤病史的ctDNA检测用于I I期或III期结直肠癌手术切除标本中微小残留病灶，并预测术后复发：CIRCULATE-Japan 中GALAXY研究的亚组分析
Yoshiaki Nakamura,Kristiyana Kaneva,Christine Lo et al.
Yoshiaki Nakamura et al.
Purpose: Analysis of circulating tumor DNA (ctDNA) may enable early identification of patients likely to relapse, presenting an opportunity for early interventions and improved outcomes. Tumor-naïve plasma-only approache...
Pathogenic variants in cancer susceptibility genes predispose to Ductal Carcinoma In situ of the breast [0.03%]
致癌基因的致病突变会增加乳腺导管原位癌的发病风险
Huaizhi Huang,Ronan E Couch,Rachid Karam et al.
Huaizhi Huang et al.
Purpose: To determine the relationship between germline pathogenic variants (PVs) in cancer predisposition genes and the risk of ductal carcinoma in situ (DCIS). ...
Utilizing Patient-derived Xenografts to Model Precision Oncology for Biliary Tract Cancer [0.03%]
利用患者来源的异种移植体 modeling biliary tract cancer的精准肿瘤学
Timothy P DiPeri,Kurt W Evans,Stephen Scott et al.
Timothy P DiPeri et al.
Purpose: Biliary tract cancers (BTCs), which are rare and aggressive malignancies, are rich in clinically actionable molecular alterations. A major challenge in the field is the paucity of clinically relevant BTC models w...
Re-irradiation plus pembrolizumab: Phase II study for recurrent glioblastoma patients [0.03%]
再放疗联合派姆单抗治疗复发性胶质母细胞瘤患者的II期临床研究
Fabio M Iwamoto,Shyam K Tanguturi,Lakshmi Nayak et al.
Fabio M Iwamoto et al.
Purpose: Radiation therapy may enhance anti-tumor immune responses by several mechanisms including induction of immunogenic cell death. We performed a phase 2 study of pembrolizumab with re-irradiation in patients with re...
Targeting c-MET for Endoscopic Detection of Dysplastic Lesions Within Barrett's Esophagus Using EMI-137 Fluorescence Imaging [0.03%]
靶向c-MET用于巴雷特食管内镜检测EMI-137荧光成像的异常病灶
Yi-Jhih Huang,Jonas Rieder,Kel Vin Tan et al.
Yi-Jhih Huang et al.
Purpose: Esophageal cancer (EC) carries a poor prognosis with 5-year overall survival of less than 20%. Barrett's esophagus (BE) increases the risk of esophageal adenocarcinoma (EAC). The aim of this study was to investig...
Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration Resistant Prostate Cancer [0.03%]
杜瓦鲁单抗联合或不联合特莫珠单抗治疗转移性去势抵抗性前列腺癌患者的II期随机研究
Eric Winquist,Sebastien J Hotte,Kim Chi et al.
Eric Winquist et al.
Purpose: Programmed death-ligand 1 (PD-L1) is overexpressed by dendritic cells in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing on androgen receptor pathway inhibitors. We tested whethe...
BRAF deletion in adult patients with Langerhans cell histiocytosis correlates with multisystem disease and poor outcome [0.03%]
成人朗格汉斯细胞组织细胞增生症中BRAF基因的缺失与多系统疾病及预后不良相关
Min Lang,Long Chang,Hao Cai et al.
Min Lang et al.
Background: Langerhans cell histiocytosis (LCH) is a rare and highly heterogeneous histiocytosis. There are currently few studies examining the correlation between molecular profiling and clinical phenotype or outcome in ...
Genomic, epigenomic and transcriptomic inter- and intra-tumor heterogeneity in desmoid tumors [0.03%]
(desmoid肿瘤的)基因组、表观基因组和转录组的异质性
Chelsea De Bellis,Sujay Vennam,Christopher Eeles et al.
Chelsea De Bellis et al.
Purpose: Desmoid tumors are bland fibroblastic tumors that do not metastasize but have a high rate of local recurrence. Previously published studies proposed two different transcriptomic signatures to predict relapse. Mol...